Liver X Receptor
- Inhibitory Selectivity
- Solubility
| Catalog No. | Product Name | Solubility(25°C) | ||
|---|---|---|---|---|
| Water | DMSO | Alcohol | ||
| S2630 | GW3965 HCl | <1 mg/mL | 16 mg/mL | <1 mg/mL |
| S7076 | T0901317 | <1 mg/mL | 96 mg/mL | 96 mg/mL |
| S8689 | RGX-104 | 100 mg/mL | <1 mg/mL | |
| S8390 | LXR-623 (WAY-252623) | <1 mg/mL | 84 mg/mL | 84 mg/mL |
| S7934 | SR9243 | <1 mg/mL | <1 mg/mL | <1 mg/mL |
Liver X Receptor Products
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S2630 |
GW3965 HClGW3965 HCl is a potent, selective LXR agonist for hLXRα and hLXRβ with EC50 of 190 and 30 nM in cell-free assays, respectively. |
a. Western blot analysis for EpCAM, PKM2, and CK19 expression in livers from C57BL/6J mice treated with DDC for 1 week in the absence or presence of GW3965 (10 mg/kg; n = 4 per group). *P < 0.05, **P < 0.01. c Western blot analysis of p-STAT3, t-STAT3, and SOCS3 in WB-F344 cells treated with GW3965 (5 μM) or DMSO as control in response to IL-6 (50 ng/ml) treatment for 0, 0.25, 0.5, 0.75, 1, and 2 h.
|
|
| S7076 |
T0901317T0901317 is a potent and selective agonist for both LXR and FXR, with EC50 of ~50 nM and 5 μM, respectively. |
THP-1 macrophages were pretreated with 5 μg/mL T0901317 for 30 min and incubated with 100 μmol/L Hcy for 24 h. protein levels were determined.
|
|
| S8689New |
RGX-104RGX-104 is a orally bioavailable liver X receptor agonist that modulates innate immunity via transcriptional activation of the ApoE gene. |
||
| S8390 |
LXR-623 (WAY-252623)LXR-623 is a novel liver X-receptor(LXR) agonist with IC50 values of 179 nM and 24 nM for LXR-α and LXR-β, respectively. It is orally bioavailable and readily passes the blood-brain barrier. |
||
| S7934 |
SR9243SR9243 is a potent and selective LXR inverse agonist. |
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S2630 |
GW3965 HClGW3965 HCl is a potent, selective LXR agonist for hLXRα and hLXRβ with EC50 of 190 and 30 nM in cell-free assays, respectively. |
2017, 91(1):271-287 2018, 304:21-29 2015, 589(1):52-8 |
a. Western blot analysis for EpCAM, PKM2, and CK19 expression in livers from C57BL/6J mice treated with DDC for 1 week in the absence or presence of GW3965 (10 mg/kg; n = 4 per group). *P < 0.05, **P < 0.01. c Western blot analysis of p-STAT3, t-STAT3, and SOCS3 in WB-F344 cells treated with GW3965 (5 μM) or DMSO as control in response to IL-6 (50 ng/ml) treatment for 0, 0.25, 0.5, 0.75, 1, and 2 h.
|
| S7076 |
T0901317T0901317 is a potent and selective agonist for both LXR and FXR, with EC50 of ~50 nM and 5 μM, respectively. |
2018, 10.1016/j.lfs.2018.10.060 2017, 12(1):322 2015, 589(1):52-8 |
THP-1 macrophages were pretreated with 5 μg/mL T0901317 for 30 min and incubated with 100 μmol/L Hcy for 24 h. protein levels were determined.
|
| S8689New |
RGX-104RGX-104 is a orally bioavailable liver X receptor agonist that modulates innate immunity via transcriptional activation of the ApoE gene. |
||
| S8390 |
LXR-623 (WAY-252623)LXR-623 is a novel liver X-receptor(LXR) agonist with IC50 values of 179 nM and 24 nM for LXR-α and LXR-β, respectively. It is orally bioavailable and readily passes the blood-brain barrier. |
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S7934 |
SR9243SR9243 is a potent and selective LXR inverse agonist. |
2016, 590(11):1614-29 |
